Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / Companies / Mapp Biopharmaceutical
Entity

Mapp Biopharmaceutical

Tracked across 6 events · 844 articles · First seen Mar 09, 2018 · Last active Aug 14, 2026

Sentiment
30
Attention
8
Events
6
Relationships
22
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
Events (6)
4 80
Regulatory
FDA Approves ArkBio Ziresovir Phase II Trial
Mapp Biopharmaceutical Co., Ltd. (ArkBio) announced that the U.S. United States — Food and Drug Administration (FDA) has approved ziresovir (AK0529) for a phase II clinical trial in severely ill RSV-infected infants, including those in…
Impact: ArkBio is the developer of ziresovir and the recipient of the FDA approval, marking a significant advancement in its lead pipeline asset and potentially increasing its commercial prospects.
Jul 20, 2026 · 6 articles
2 20
Business
Emcure acquires full Gennova stake
Impact: Becomes a wholly-owned subsidiary of Emcure, with a renewed focus on biologics and biosimilars under new CEO Amit Mehta. The mRNA business has been divested.
Jul 13, 2026 · 7 articles
6 60
Tech
WHO Prioritizes Ebola Bundibugyo Treatments
Impact: Mapp Biopharmaceutical developed MBP134, one of the experimental treatments prioritized by the World Health Organization for the Bundibugyo strain of Ebola.
May 28, 2026 · 6 articles
6 10
Accidents
DRC Bundibugyo Ebola outbreak fastest-growing
Impact: Supplying experimental MBP134 antibody for trials; potential positive impact if treatment proves effective.
Mar 09, 2018 · 314 articles
8 10
Accidents
Unknown Event
Impact: Mapp Biopharmaceutical>>>'s pan-ebolavirus antibody drug, MBP134, is a potential candidate for clinical trials against the Uganda — Bundibugyo strain, with development backed by BARDA.
May 18, 2026 · 505 articles
4 0
Regulatory
Beyond_Air Nasdaq Listing Extension Granted
Impact: q.beyond terminated its proposed transaction with Mapp Biopharmaceutical for the sale of its NeuroNOS subsidiary, indicating a change in strategic plans for q.beyond's assets.
Jun 01, 2026 · 6 articles
Key Actions (2)
100 United States — Food and Drug Administration approved Mapp BiopharmaceuticalFDA Approves ArkBio...
50 Mapp Biopharmaceutical enrolled patient Democratic Republic of the CongoDRC Ebola outbreak spreads...
Relationships (22)
Gilead Sciences partner ↔ Mapp Biopharmaceutical Mapp Biopharmaceutical is collaborating with Gilead Sciences on clinical trials
Gilead Sciences partner ↔ Mapp Biopharmaceutical Gilead Sciences is collaborating with Mapp Biopharmaceutical on clinical trials
Serum Institute of India ↔ Mapp Biopharmaceutical
Serum Institute of India ↔ Mapp Biopharmaceutical
International AIDS Vaccine Initiative ↔ Mapp Biopharmaceutical
International AIDS Vaccine Initiative ↔ Mapp Biopharmaceutical
Tedros Adhanom Ghebreyesus ↔ Mapp Biopharmaceutical
Tedros Adhanom Ghebreyesus ↔ Mapp Biopharmaceutical
Merck & Co. ↔ Mapp Biopharmaceutical
Merck & Co. ↔ Mapp Biopharmaceutical
Regeneron Pharmaceuticals ↔ Mapp Biopharmaceutical
Regeneron Pharmaceuticals ↔ Mapp Biopharmaceutical
Uganda ↔ Mapp Biopharmaceutical
Uganda ↔ Mapp Biopharmaceutical
Democratic Republic of the Congo ↔ Mapp Biopharmaceutical
Democratic Republic of the Congo ↔ Mapp Biopharmaceutical
World Health Organization ↔ Mapp Biopharmaceutical
World Health Organization ↔ Mapp Biopharmaceutical
United States — Centers for Disease Control and Prevention ↔ Mapp Biopharmaceutical
United States — Centers for Disease Control and Prevention ↔ Mapp Biopharmaceutical
United States ↔ Mapp Biopharmaceutical
United States ↔ Mapp Biopharmaceutical
ERGEN INTELLIGENCE
Track Mapp Biopharmaceutical live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.